Validation of a blood-based autoantibody test to assess lung cancer risk in 4–30 mm pulmonary nodules: a retrospective pooled analysis of four cohort studies

AAT provides size- and risk-independent, high-specificity rule-in performance, identifying subsets of patients whose malignancy risk may justify expedited evaluation.